GLP-1 Drugs for Diabetes in 2008: Exenatide, Sitagliptin, and Pramlintide From a Cost Perspective
Three new peptide-based diabetes drugs (exenatide/GLP-1, sitagliptin/DPP-4, pramlintide/amylin) evaluated from a managed care perspective for cost-effectiveness, positioning, and optimal patient selection.
Quick Facts
What This Study Found
Managed care analysis of exenatide (GLP-1 agonist: weight loss, injectable), sitagliptin (DPP-4 inhibitor: oral, weight neutral), and pramlintide (amylin analog: injectable, weight loss) for T2DM positioning — incretin drugs transforming diabetes pharmacotherapy economics.
Key Numbers
How They Did This
review study.
Why This Research Matters
Relevant for glp-1, exenatide, diabetes.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Managed care analysis of exenatide (GLP-1 agonist: weight loss, injectable), sitagliptin (DPP-4 inhibitor: oral, weight neutral), and pramlintide (amy
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2008.
- Original Title:
- Managed care perspective on three new agents for type 2 diabetes.
- Published In:
- Journal of managed care pharmacy : JMCP, 14(4), 363-80 (2008)
- Authors:
- VanDeKoppel, Shawna, Choe, Hae Mi, Sweet, Burgunda V
- Database ID:
- RPEP-01430
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was studied?
GLP-1 Drugs for Diabetes in 2008: Exenatide, Sitagliptin, and Pramlintide From a Cost Perspective
What was found?
Three new peptide-based diabetes drugs (exenatide/GLP-1, sitagliptin/DPP-4, pramlintide/amylin) evaluated from a managed care perspective for cost-effectiveness, positioning, and optimal patient selection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01430APA
VanDeKoppel, Shawna; Choe, Hae Mi; Sweet, Burgunda V. (2008). Managed care perspective on three new agents for type 2 diabetes.. Journal of managed care pharmacy : JMCP, 14(4), 363-80. https://doi.org/10.18553/jmcp.2008.14.4.363
MLA
VanDeKoppel, Shawna, et al. "Managed care perspective on three new agents for type 2 diabetes.." Journal of managed care pharmacy : JMCP, 2008. https://doi.org/10.18553/jmcp.2008.14.4.363
RethinkPeptides
RethinkPeptides Research Database. "Managed care perspective on three new agents for type 2 diab..." RPEP-01430. Retrieved from https://rethinkpeptides.com/research/vandekoppel-2008-managed-care-perspective-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.